Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216105 | 0.95 | HRH1 (0.33) | KCNH2HRH3 | |
| SCHEMBL15415063 | 0.90 | — | — | |
| SCHEMBL19410901 | 0.77 | IDH1 (0.30) | — | |
| SCHEMBL1654018 | 0.74 | CYP11B2 (0.33) | — | |
| SCHEMBL1521725 | 0.74 | DRD2 (0.40) | — | |
| SCHEMBL542167 | 0.70 | — | — | |
| SCHEMBL11777192 | 0.69 | ALDH1A1 (0.43) | MAPK8MAPK9MAPK10HRH3 | |
| SCHEMBL19410904 | 0.69 | — | — | |
| SCHEMBL1608271 | 0.68 | — | — | |
| SCHEMBL15415679 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109195968-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-109195969-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-12-21 | — | — | CN | claimed |
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2021-02-02 | — | — | US | claimed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| CN-109195968-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-109219609-B | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-109219608-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-109195969-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3436456-B1 | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3436460-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-08-18 | — | — | EP | disclosed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2015086498-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086507-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | MAPK8 895/4885MAPK9 1832/4885MAPK10 1518/4885 |
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | MAPK8 625/4885MAPK9 1499/4885MAPK10 1236/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | MAPK8 625/4885MAPK9 1499/4885MAPK10 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.